MedPath

EFFECTIVENESS OF THE NEUROADAPTATIVE FOR URGE INCONTINENCE

Not Applicable
Conditions
Urge Incontinence
Registration Number
NCT04164589
Lead Sponsor
Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias
Brief Summary

In this clinical trials the sponsor want to assess a self-controlled-energo-neuroadaptative-regulation in patient with urge incontinence

Detailed Description

In this clinical trials the sponsor want to assess a self-controlled-energo-neuroadaptative-regulation in patient with urge incontinence and mixted incontinence

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
62
Inclusion Criteria
  • Urge incontinence or mixed incontinence without urethral hypermobility
  • Over 3 months of disease evolves.
Exclusion Criteria
  • Severe physical limitations that might interfere with applying the treatment.
  • Severe mental disorders that need pharmacology treatments that may influence in neuronal activity
  • Oncological processes in the lower abdomen that had required radical surgery.
  • Neurogenic bladder.
  • Blockage of the bladder
  • Vaginal infection
  • Bladder infection or disorder of kidney function
  • Have received, in the last year, botulinum toxin in bladder or pelvic organs.
  • Have received pharmacological treatment for urge incontinence in the last month (before entry date in the trial)
  • Be receiving pharmacological treatment for urge incontinence.
  • Stress incontinence due to urethral hypermobility which was treatable with surgery.
  • Pregnant women
  • Patients with pacemarker

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Resultant value achieved in the assessment scale of urge incontinence.2 years

Resultant value achieved in the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI-SF). The ICIQ-UI Short Form is a questionnaire for evaluating the frequency, severity and impact on quality of life (QoL) of urinary incontinence. Question items: Frequency or urinary incontinence; Amount of leakage; Overall impact of urinary incontinence; Self-diagnostic ítem. Scoring scale: 0-21. Higher score mean a worse outcome.

Sandvik Test for Urinary Incontinence2 years

It is a severity indez score of symptoms to calculate severity of urinary incontinence in women. Scores are from 0 to 12. The higher score: the more severe the urinary incontinence.

Secondary Outcome Measures
NameTimeMethod
Satisfaction with the treatment (Visual analogue scale.)2 years

Visual analogue scale. Minimun values: 0, máximum values: 10. Higher score means a high satisfaction with the treatment received.

Quality of life index (Potenziani-14-CI-IO-QOL-2000 index)2 years

Impact of incontinence on quality of life. Scores are from 0 to 28. Slight impact in quality of life = 0-14. Higher impact in quality of life = 15-28.

Duration of the response to treatment2 years

the duration of the response to treatment

Frequency of nocturia2 years

Frequency of nocturia

Intervals between voiding2 years

time between voiding

Trial Locations

Locations (1)

Álvaro Zapico-Goñi

🇪🇸

Madrid, Spain

Álvaro Zapico-Goñi
🇪🇸Madrid, Spain
Alvaro Zapico-Goñi, M.D
Contact
918878100
azapicog1@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.